PubMed Health⌕ Search

PubMed · 16459594

Molecular simulation evidence for solidlike adsorbate in complex carbonaceous micropore structures.

Abstract

Adsorption of a model nitrogen vapor on a range of complex nanoporous carbon structures is simulated by grand canonical Monte Carlo simulation for a single subcritical temperature above the bulk freezing point. Adsorption and desorption isotherms, heats of adsorption, and three-dimensional singlet distribution functions (SDFs) were generated. Inspection of the SDFs reveals significant levels of solidlike adsorbate at saturation even in the most complex of the microporous solids considered. This strongly suggests that solidlike adsorbate will also occur for simple subcritical vapors adsorbed on real noncrystalline solids such as microporous carbons at temperatures above the bulk freezing point, supporting indirect experimental observations. The presence of significant levels of solidlike adsorbate has implications for characterization of microporous solids where adsorbate density is used (e.g., determination of pore volume from loading). Detailed consideration of the SDF at different loadings for a model microporous solid indicates solidlike adsorbate forms at distributed points throughout the pore space at pressures dependent on the nature of the local porosity. The nature of the local porosity also dictates the freezing mechanism. A local freezing/ melting/refreezing process is also observed. Introduction of mesoporosity into the model causes hysteresis between the adsorption and desorption isotherms. Adsorption in the hysteresis loop occurs by a series of local condensation events. It appears as if the presence of adjacent microporosity and/or adsorbate within it affects the pressure at which these events occur. Reversal of the condensation during desorption occurs throughout the mesoporosity at a single pressure; this pressure is unaffected by the presence of adjacent microporosity or the adsorbate within it. It is also shown that the empirical concept of "pore size" is not consistent for describing adsorption in the complex solids considered here. A new concept is, therefore, proposed that seeks to account for the factors that affect local adsorption energy: local geometry, microtexture, surface atom density, and surface chemistry.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Mark J Biggs, Alex Buts, David Williamson. 2004-07-06. Molecular simulation evidence for solidlike adsorbate in complex carbonaceous micropore structures.. https://doi.org/10.1021/la036269o

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗